



**Strong clinical adoption confirmed:
+115% growth in treatment numbers driven by
German and Asian thyroid market**

Malakoff – May 24, 2016 – THERACLION (Alternext, FR0010120402 – ALTHE), a company specialized in leading-edge medical equipment for echotherapy, announces today strong uptake in the number of echotherapy treatments performed around the world. Since introduction of echotherapy in 2004, 620 treatments have been performed including a major acceleration of treatment activities observed in the past 4 months.

Initially utilized for clinical investigation purposes only in 2004, treatment volume increased meaningfully in 2013 when the first system received marketing authorization. In 2015, a commercialization inflexion point was achieved with 16 commercial agreements in place with recognizable continuation of this trend in 2016.

Observed commercial success has now translated into clinical adoption: in the first 4 months of 2016, +115% more treatments have been performed compared to the same period in 2015. 2016 treatments represent 18% of overall clinical activity to date.

In particular, the number of thyroid echotherapy treatments increased eightfold over the first four months of 2016 compared to the same period in 2015. Echotherapy is particularly interesting for the treatment of thyroid nodules, representing for Germany alone a cost savings potential of up to 50% compared to standard surgery. In addition, echotherapy is an ambulatory procedure requiring 1-2 hours versus 3 to 5 days of hospitalization following conventional surgery.

Germany is Theraclion's strongest market with 8 sites now offering echotherapy to patients and about one quarter of all global treatments performed there. 16 agreements with health insurers assure coverage and patient access to echotherapy treatments for breast fibroadenoma and benign thyroid nodules.

The region with the biggest market potential is Asia, with a particular focus on China and Korea. According to a peer reviewed scientific study¹, the market in China is of particular importance with almost 1 million thyroid surgeries performed every year. Within the \$6-8 billion annual thyroid surgery market world-wide, China spends nearly \$2 billion on thyroid surgical procedures representing a large opportunity for healthcare spend reduction using non-invasive techniques.

"We are pleased to see our growth materializing with significant clinical adoption of echotherapy in our installed base enabling more patient access to non-invasive treatment. Enhanced access to the German and Asian thyroid markets reflects a key inflexion point in our commercial expansion." says David Caumartin, CEO of Theraclion.

¹ Liu at al., Annual Financial Impact of Thyroidectomies for Nodular Thyroid Disease in China, Asian Pacific Journal of Cancer Prevention, Vol 15, 2014



About Theraclion

Theraclion is a French company specializing in high-tech medical equipment using therapeutic ultrasound. Drawing on leading-edge technologies, Theraclion has designed and manufactured an innovative solution for echotherapy, the Echopulse®, allowing non-invasive tumor treatment through ultrasound-guided high-intensity focused ultrasound. Theraclion is ISO 13485 certified and has received the CE mark for non-invasive ablation of breast fibroadenomas and thyroid nodules. Based in Malakoff, near Paris, France. Theraclion has brought together a team of 34 people, 50 percent of whom are dedicated to R&D and clinical trials. For more information, please visit Theraclion's website: www.theraclion.com.

Theraclion is listed on Alternext Paris.

PEA-PME eligible

Mnemonic: ALTHE - ISIN Code: FR0010120402



Contact:

Theraclion

David Caumartin

Chief Executive Officer

Tel.: +33 (0)1 55 48 90 70

david.caumartin@theraclion.com

NewCap

Financial Communication and Relations

Emmanuel Huynh / Valentine Brouchet

Tel.: +33 (0)1 44 71 94 94

theraclion@newcap.eu

Kalima

Press Relations

Estelle Reine-Adélaïde / Florence Calba

Tel.: + 33 (0)1 44 90 82 54

era@kalima-rp.fr